Align Technology settles patent litigation with Ormco

Align Technology, Inc. today announced that it has reached a settlement with Ormco Corporation (Ormco), a subsidiary of Danaher Corporation, to end all pending litigation between the parties and to begin a new strategic collaboration.

As part of the settlement, Align will make a cash payment of approximately $13 million to Ormco and issue approximately 7.6 million shares of Align's Common Stock to Danaher Corporation, Ormco's ultimate parent, that after issuance will be equal to approximately ten percent ownership interest in Align. Based on the closing price of Align's Common Stock on Friday, August 14, 2009 the value of the shares is approximately $77 million. The issuance of a portion of the shares is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. For a summary of the terms of the transaction, please refer to the Company's Form 8-K filed today.

Align and Ormco have also agreed upon an exclusive collaboration over the next seven years to develop and market an orthodontic product that combines the Invisalign(R) system with Ormco's Insignia(R) orthodontic brackets and arch wires system to treat the most complex cases. Each party will retain ownership of its pre-existing intellectual property, and each party will be granted intellectual property licenses in their respective field for jointly-developed combination products.

"We are pleased to resolve this ongoing litigation with Ormco and to begin a new relationship that meets our shared goals of providing innovative products and excellent service to our orthodontic customers," said Thomas M. Prescott, Align Technology president and CEO. "This collaboration with Ormco, a fellow innovator in digital orthodontics, gives us the ability to compete for a segment of the market that is difficult to treat with Invisalign alone, and accelerates our long-term plan for a combination product."

Per the terms of the agreement, Ormco and Align have requested that judgment be entered on the claims resolved by the jury and all remaining claims in the litigation between the two parties be dismissed with prejudice. Additionally, as part of the settlement agreement, Ormco has agreed to release all past claims asserted by Ormco against Align based upon the '444 patent and has agreed not to sue Align for any claim of infringement based upon the '444 patent as a result of Align's relating to removable aligners.

www.invisalign.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Danaher. (2009, August 17). Align Technology settles patent litigation with Ormco. News-Medical. Retrieved on April 18, 2024 from https://www.news-medical.net/news/20090817/Align-Technology-settles-patent-litigation-with-Ormco.aspx.

  • MLA

    Danaher. "Align Technology settles patent litigation with Ormco". News-Medical. 18 April 2024. <https://www.news-medical.net/news/20090817/Align-Technology-settles-patent-litigation-with-Ormco.aspx>.

  • Chicago

    Danaher. "Align Technology settles patent litigation with Ormco". News-Medical. https://www.news-medical.net/news/20090817/Align-Technology-settles-patent-litigation-with-Ormco.aspx. (accessed April 18, 2024).

  • Harvard

    Danaher. 2009. Align Technology settles patent litigation with Ormco. News-Medical, viewed 18 April 2024, https://www.news-medical.net/news/20090817/Align-Technology-settles-patent-litigation-with-Ormco.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Danaher acquires Life Technologies' mass spectrometry business